XNCR Stock Risk & Deep Value Analysis
Xencor Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About XNCR Stock
We analyzed Xencor Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran XNCR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is XNCR Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Medium
What Are the Red Flags for XNCR?
- ⚠
Failure to secure adequate financing leading to liquidity crisis or severe dilution
- ⚠
Negative clinical trial readouts or development setbacks for key programs
- ⚠
Increased cash burn rate exceeding projections
- ⚠
Termination of a significant partnership
Unlock XNCR Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Xencor Inc (XNCR) Do?
Market Cap
$1.08B
Sector
Healthcare
Industry
Biotechnology
Employees
250
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Visit Xencor Inc WebsiteIs XNCR Stock Undervalued?
Unlock the full AI analysis for XNCR
Get the complete DVR score, risk analysis, and more
Does XNCR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
The XmAb platform is scientifically robust, with a track record of generating diverse drug candidates that address complex biological targets. This proprietary technology, backed by a strong patent estate and existing partnerships, provides a durable competitive advantage in the specialized field of antibody engineering. Long development timelines in biotech further entrench its proprietary position for current and future programs.
Moat Erosion Risks
- •Technological obsolescence or emergence of superior antibody engineering platforms
- •Failure of pipeline candidates in late-stage clinical trials
- •Loss of key scientific talent or intellectual property disputes
- •Inability to adequately fund pipeline development or commercialization initiatives
XNCR Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive XNCR Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated late April 2026)
- •Financing Update / Strategic Transaction Announcement (imminent need)
- •Clinical trial updates for key XmAb pipeline candidates (e.g., XmAb808 Phase 2 data)
Medium-Term (6-18 months)
- •Initiation of new clinical trials for additional XmAb candidates
- •Expansion of existing partnerships or formation of new collaborations
- •Advancement of partnered programs into later-stage clinical development
Long-Term (18+ months)
- •Regulatory approval and commercialization of a wholly-owned XmAb product
- •Significant revenue generation from multiple partnered programs
- •XmAb platform becoming a standard in specific therapeutic areas
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for XNCR?
- ✓
Announcement of new financing, especially non-dilutive deals or a strategic acquisition
- ✓
Positive Phase 2 or Phase 3 clinical trial readouts for key pipeline candidates
- ✓
Significant new partnership agreements or expansion of existing collaborations
- ✓
Clear improvements in cash burn rate and extension of cash runway guidance
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for XNCR (Xencor Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
